Search Results

By CHARLES L. BENNETT, MD, PhD, MPP; STEVEN T. ROSEN, MD; AND GERARD F. ANDERSON, PhD  / July 2025

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list price. This new price will go into effect in January 2026. Negotiations began following passage...